Massimo Giusti, MD
Cardiology · Richmond, VANPI 1720011398
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.2% of the total across 125 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 12.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $492 and has fallen 83.7% since, to $80 in 2025.
Across 125 payments — averaging $16.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$273
- Amgen$250
- Novartis$244
- Boston Scientific$192
- E.r. Squibb & Sons, L.L.C.$160
- Boehringer Ingelheim$146
- plus $849 from 17 others
What the payments were for
- Food & beverage$1,99194%
- Education$1236%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 17 | $273 |
| Amgen | 16 | $250 |
| Novartis | 15 | $244 |
| Boston Scientific | 7 | $192 |
| E.r. Squibb & Sons, L.L.C. | 13 | $160 |
| Boehringer Ingelheim | 8 | $146 |
| Astellas Pharma US Inc | 7 | $129 |
| Actelion Pharmaceuticals US, Inc. | 4 | $128 |
| Johnson & Johnson | 6 | $81 |
| Esperion Therapeutics, Inc. | 6 | $79 |
| Sanofi-aventis U.S. LLC | 3 | $63 |
| Regeneron Healthcare Solutions, Inc. | 4 | $59 |
| Philips North America LLC | 3 | $52 |
| Merck | 3 | $49 |
| Heartflow, Inc. | 2 | $46 |
| Novo Nordisk | 2 | $35 |
| Lundbeck LLC | 2 | $28 |
| Atricure, Inc. | 1 | $20 |
| Cvrx, Inc. | 2 | $19 |
| Irhythm Technologies, Inc. | 1 | $18 |
| Abiomed | 1 | $16 |
| Gilead | 1 | $14 |
| Medtronic | 1 | $13 |
How this compares
Too few cardiology providers in Virginiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 430 | $499,713 |
| EntrestoSacubitril/Valsartan | 181 | $218,917 |
| Repatha SureclickEvolocumab | 38 | $59,740 |
| XareltoRivaroxaban | 37 | $48,598 |
| JardianceEmpagliflozin | 36 | $48,289 |
| Praluent PenAlirocumab | 35 | $31,966 |
| FarxigaDapagliflozin Propanediol | 22 | $19,369 |
| Repatha PushtronexEvolocumab | 16 | $13,641 |
| Metoprolol Succinate | 469 | $5,385 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 11 | $4,878 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 53 | $3,477 |
| Isosorbide Dinitrate | 43 | $2,640 |
| Carvedilol ErCarvedilol Phosphate | 15 | $2,450 |
| Rosuvastatin Calcium | 164 | $2,397 |
| Amiodarone Hcl | 64 | $2,328 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $273 | $499,713430 claims |
| NovartisEntresto | $244 | $218,917181 claims |
| Johnson & JohnsonXarelto | $81 | $48,59837 claims |
| Boehringer IngelheimJardiance | $146 | $48,28936 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cardiology providers in Virginiaon file to place this against a meaningful peer group, so we don't.
Other cardiology in Richmond
- John OwensRichmond$4K
- Mark WarnerRichmond$3K
- Fareeha KhanVienna$66K
- Shakil KhanMidlothian$4K
- Gareth TitusSouth Boston$3K
- Derrick RidleyHampton$2K
- Khosro ShareghiWoodbridge$985
- Rafael AriasFalls Church$514
- M ZaheerArlington$285
- Dean CarpousisArlington$96
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.